Trial · NCT02578095
Acute Hip Fracture Study in Patients 65 Years or Greater
NCT02578095, Phase 2, Completed, Viking Therapeutics, Inc.; results first posted 2025-12-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Acute Hip Fracture Study in Patients 65 Years or Greater. Trials, record NCT02578095. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02578095
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Acute Hip Fracture Study in Patients 65 Years or Greater
- NCT number
- NCT02578095
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 108 participants, actual
- Lead sponsor
- Viking Therapeutics, Inc.
- Conditions
- Hip Fractures
- Interventions
- VK5211, Placebo
- First posted
- 2015-10-16
- Last updated
- 2025-12-29
- Results first posted
- 2025-12-29
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efficacy in Hip Fracture Patients Confirmed by DXA Scan. | Baseline and Week12 | Efficacy of VK5211 after 12 weeks of treatment by mean placebo-corrected percentage change in total body less head (TBLH) lean body mass assessed by whole body dual-energy x-ray absorptiometry scan (DXA) scan. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Efficacy in Hip Fracture Patients Confirmed by DXA Scan. | Baseline and Week12 | The ITT population was the primary analysis population for assessing efficacy. | PBO adjusted percent change | LEAST_SQUARES_MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Efficacy in Hip Fracture Patients Confirmed by DXA Scan. | Placebo | 0 | 95% Confidence Interval 0 to 0 | PBO adjusted percent change | |
| Efficacy in Hip Fracture Patients Confirmed by DXA Scan. | VK5211- 0.5mg | 4.75 | 95% Confidence Interval 1.70 to 7.80 | PBO adjusted percent change | |
| Efficacy in Hip Fracture Patients Confirmed by DXA Scan. | VK5211- 1.0mg | 7.15 | 95% Confidence Interval 3.76 to 10.54 | PBO adjusted percent change | |
| Efficacy in Hip Fracture Patients Confirmed by DXA Scan. | VK5211- 2.0mg | 9.08 | 95% Confidence Interval 5.55 to 12.60 | PBO adjusted percent change |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 28 | |
| Overall Study | STARTED | VK5211- 0.5mg | 29 | |
| Overall Study | STARTED | VK5211- 1.0mg | 26 | |
| Overall Study | STARTED | VK5211- 2.0mg | 25 | |
| Overall Study | COMPLETED | Placebo | 19 | |
| Overall Study | COMPLETED | VK5211- 0.5mg | 22 | |
| Overall Study | COMPLETED | VK5211- 1.0mg | 17 | |
| Overall Study | COMPLETED | VK5211- 2.0mg | 17 | |
| Overall Study | NOT COMPLETED | Placebo | 9 | |
| Overall Study | NOT COMPLETED | VK5211- 0.5mg | 7 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events372
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Placebo | 1 | 28 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | VK5211- 0.5mg | 0 | 29 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | VK5211- 1.0mg | 0 | 26 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | VK5211- 2.0mg | 2 | 25 | 2 |
| other | Atrial Fibrillation | Cardiac disorders | Placebo | 0 | 28 | 0 |
| other | Atrial Fibrillation | Cardiac disorders | VK5211- 0.5mg | 1 | 29 | 1 |
| other | Atrial Fibrillation | Cardiac disorders | VK5211- 1.0mg | 0 | 26 | 0 |
| other | Atrial Fibrillation | Cardiac disorders | VK5211- 2.0mg | 0 | 25 | 0 |
| other | Cardiac Failure | Cardiac disorders | Placebo | 0 | 28 | 0 |
| other | Cardiac Failure | Cardiac disorders | VK5211- 0.5mg | 0 | 29 | 0 |
1 to 10 of 372Source ClinicalTrials.gov
See all 372 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | 0 | 28 |
| Total, all-cause mortality | VK5211- 0.5mg | 0 | 29 |
| Total, all-cause mortality | VK5211- 1.0mg | 0 | 26 |
| Total, all-cause mortality | VK5211- 2.0mg | 0 | 25 |
| Total, other adverse events | Placebo | 10 | 28 |
| Total, other adverse events | VK5211- 0.5mg | 11 | 29 |
| Total, other adverse events | VK5211- 1.0mg | 8 | 26 |
| Total, other adverse events | VK5211- 2.0mg | 16 | 25 |
| Total, serious adverse events | Placebo | 4 | 28 |
| Total, serious adverse events | VK5211- 0.5mg | 2 | 29 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02578095
GET https://conductscience.org/api/trials/v1/NCT02578095/events?page=2